食管癌前增生营养阻断研究初步报告  

A Preliminary Report of Nutritional Intervention in Dysplasia of the Esophagus

作　　者：沈琼[1] 王东煜[1] 项芸岩 王超[1] 任知春[1] 阎爱华[1] 任秀花[1] 常福聚[1] 张锦霞[1] 叶颖江[1] 周英发[1] 黄梅[1,2] 郑虎智 蔡祥生 陈化民 张介卿 常云峰 罗东升 

机构地区：[1]河南医科大学癌前期研究室 [2]河南医科大学卫生系 [3]河南省鹤壁市肿瘤研究所

出　　处：《中国肿瘤临床》1991年第1期32-34,共3页Chinese Journal of Clinical Oncology

摘　　要：1988年8月起在食管癌高发区鹤壁市郊居民中,采用随机分组双盲对照,对1006名食管轻,重度增生患者进行复合核黄素营养干预研究。在服药15个月后进行了第1次食管细胞学复查。初步结果显示,轻增患者疗效不明显;实验组重度增生好转率略高于对照组,进展率略低于对照组,实验组重增癌变率较对照组减少77.2％(P<0.05)。说明复合核黄素对食管上皮重度增生癌变的抑制作用明显。对重度增生的治疗(逆转)作用也是存在的。Since Aug 1988, a randomized double-blind nutritional intervention trial, including 1006 subjects with hyperplasin or dysplasia of the esophagus detected by ballon cytology in mass survey, was carriod out in the suburbs of Hebi municipality. Fif-teen months later, a follow-up cytologic screening which involved 169 dysplastic cases treated with 'Compound Riboflavin' was done and 2 cancer cases (1.2%) were detected. While in 174 subjects received the placebo as control, 9 (5.2%) cancers were found. Thus the incidence of cancer was reduced by 77.2% in the treated group as compared with that of the control. It is of statistic significance (X2 = 4.39 P<0.05). The regression rate on dysplasia in the treated group is more than that of the control. But in cases with hyperplasia the results were similar in the two groups. These preliminary results suggest that it is promising to use 'Compound Ribo-flavin' to treat dysplasia of the esophagus.

关 键 词：食管 癌前病变 营养阻断 核黄素 

分 类 号：R735.101[医药卫生—肿瘤]